REGN

Regeneron Pharmaceuticals
D

REGN

637.72
USD
2.46
(0.39%)
Pre Open
Volume
56
EPS
45
Div Yield
0.14
P/E
17
Market Cap
69,718,536,205
OverviewSignalsIdeasNews
Related Instruments
ABBV
ABBV
2.500
(1.23%)
205.150 USD
AMGN
AMGN
1.25
(0.41%)
306.95 USD
BMY
BMY
1.120
(1.90%)
60.010 USD
GILD
GILD
0.650
(0.58%)
111.800 USD
JNJ
JNJ
0.580
(0.36%)
163.690 USD
LLY
LLY
0.36
(0.04%)
821.56 USD
MRNA
MRNA
-1.160
(-3.59%)
31.120 USD
NVS
NVS
1.160
(1.04%)
112.570 USD
PFE
PFE
0.175
(0.70%)
25.190 USD
More
News
Treasury Yields Decline as Market Anticipates Fed Rate Cuts

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

7 months ago
Economy News
Novo Nordisk Surges in Profit and Sales

Novo Nordisk Surges in Profit and Sales

10 months ago
Stocks News
More

Title: Regeneron Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Regeneron Pharmaceuticals Inc. is an integrated biotechnology firm. The company was founded in 1988 and is headquartered in Tarrytown, New York. It develops, manufactures and sells medicines for serious conditions such as eye diseases, allergy and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and more. Its product line includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST and ZALTRAP. The company was founded by Alfred G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.